Innovus Pharma Expands its OTC Drug Pipeline with the Addition of OmepraCare™ (a Competitor of Prilosec® OTC)

This New Drug OmepraCare™ is Indicated for the
Treatment of Frequent Heartburn and is Expected to add Significant
Revenue to the Company

SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB
Venture Market: INNV), an emerging commercial-stage pharmaceutical
company that delivers safe, innovative and effective over-the-counter medicine
and consumer care products to improve men’s and women’s health and
respiratory diseases, today announced that it has entered into a supply
relationship with a third party to supply Innovus Pharma with omeprazole
20mg tablets and omeprazole 20mg 24 hour delayed release capsules
indicated for the treatment of frequent heartburn under the approved
abbreviated new drug application (“ANDA”) No. 207891 from the U.S. Food
and Drug Administration (“FDA”). Innovus Pharma will launch the drug
under its own trademark OmepraCare™ 20mg tablets and OmepraCare™ DR 20mg
24 hour delayed release capsules.

“We continue to execute on our plan to launch new OTC drugs in niche
therapeutic areas where there is a need for national brands to leverage
our success with FlutiCare® and other drugs and devices we have in the
United States. OmepraCare DR™ is the third ANDA OTC drug that we intend
to commercialize in the U.S. this year,” said Dr. Bassam Damaj, Innovus
Pharma’s President and Chief Executive Officer. “We believe that the
market opportunity for us with this product is fairly large given the
success of the product Prilosec® OTC and the relatively large size of
the market. Our goal is to launch OmepraCare™ in the US in the second
half of this year,” added Dr. Damaj.

“In addition, it is our current intention to add up to 10 additional
ANDA OTC products to our US drug pipeline,” he continued.

About OmepraCare

OmepraCare™ which is an OTC branded version of omeprazole and a
competitor of Prilosec® OTC, is a proton pump inhibitor to reduce
stomach acidity. It contains the #1 Doctor^† recommended
active drug molecule for treatment of frequent heartburn for 10
straight years.

OmepraCare™ is different from many other heartburn treatments. It works
by blocking the acid that causes heartburn and lasts 24 hours with one
pill each morning. It will be available at the 20mg dose tablets and 24
hour delayed release capsules in 42 counts.

It is on the World Health Organization’s List of Essential Drugs which
lists the most effective and safe medicines needed in a health system.
It was the seventh most prescribed medication in the United States, with
more than 70 million prescriptions in 2016. OmepraCare™ is comparable to
Prilosec® OTC. Coherent Market Insights has estimated that in 2017, the
global omeprazole market size was valued at approximately $2.67 billion
and is expected to have an increasing CAGR of 5.2% over the 2018 to 2026
time period.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer
goods and specialty pharmaceutical company engaged in the
commercialization, licensing and development of safe and effective
non-prescription medicine and consumer care products to improve men’s
and women’s health and vitality and respiratory diseases. Innovus Pharma
delivers innovative and uniquely presented and packaged health solutions
through its (a) OTC medicines and consumer and health products, which we
market directly, (b) commercial partners to primary care physicians,
urologists, gynecologists and therapists, and (c) directly to consumers
through our on-line channels, retailers and wholesalers. The Company is
dedicated to being a leader in developing and marketing new OTC and
branded Abbreviated New Drug Application (“ANDA”) products. The Company
is actively pursuing opportunities where existing prescription drugs
have recently, or are expected to, change from prescription (or Rx) to
OTC.

For more information, go to www.innovuspharma.com;
www.zestra.com; www.ejectdelay.com;
www.myvesele.com; www.urivarx.com;
www.sensumplus.com; www.myandroferti.com;
www.beyondhumantestosterone.com;
www.getbeyondhuman.com; www.trybeyondhuman.com;
www.recalmax.com; www.prostagorx.com;
www.xyralid.com; www.fluticare.com;
www.allervarx.com; www.apeaz.com;
www.regoxidine.com and
omepracaredr.com.

Innovus Pharma’s Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, projected revenues from OmepraCare™, estimated market for its
products, and statements about achieving its other development, growth,
commercialization, financial and staffing objectives. Readers are
cautioned not to place undue reliance on these forward-looking
statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read
the risk factors set forth in the Company’s most recent filing on Form
S-1, annual report on Form 10-K, subsequent quarterly reports filed on
Form 10-Q and other filings made with the SEC. Copies of these reports
are available from the SEC’s website or without charge from the Company.

*Prilosec® is a trademark owned by Proctor and Gamble and Astra Zeneca. ^†https://www.prilosecotc.com/en-us/check-the-facts

Contacts

Randy Berholtz
Innovus Pharma Investor Relations
Tel: +1 858
249 7865
[email protected]